At present, the treatment of early precursor T acute lymphoblastic leukemia is mainly based on chemotherapy, hematopoietic stem cell transplantation, targeted therapy and immunotherapy. 1. Patients with initial diagnosis: traditional chemotherapy is mainly used for patients with initial diagnosis, and allogeneic hematopoietic stem cell transplantation can be given after the disease is in remission. Specific drugs include cyclophosphamide, vinblastine and so on. 2. Treatment of relapsed patients: after relapse of early precursor T acute lymphoblastic leukemia patients, their treatment plan can choose traditional chemotherapy, targeted therapy, immunotherapy and so on. Specifically, it includes cetanilide, CD7-CarT cell therapy, etc. In recent years, relevant researchers have gained new insights into its genetics, subtypes, and prognostic judgments. It should be noted that clinicians need to determine different treatment options according to the specific conditions of the patients, and patients should not use medication on their own.